Dermalyser, an AI-driven tool for melanoma diagnosis, has received CE mark certification, enabling its commercial use in Europe.
Melanoma News
The bigger picture: Balancing innovation and evidence in the fight against melanoma
Every year, more than 18,000 Australians are diagnosed with invasive melanoma – the nation’s so-called “national cancer”. Another 28,000 are diagnosed with in-situ disease.
Derm Dispatch: Melanoma Doesn’t Wait—Neither Should You
In a recent interview for Dermatology Times, Renata Block, PA-C, spoke with Brittanny Groover, a melanoma survivor and passionate advocate for skin cancer awareness.
Clinical Predictors of Early Cutaneous Melanoma Recurrence
Early-stage (IA, IB, IIA) cutaneous melanoma (CM) is typically managed with wide local excision (WLE).